The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MPN Advances Day 2019 | Allo-transplant for myelofibrosis
Donal McLornan, MB BCh, MRCP, PhD, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the retrospective study by the European Society for Blood and Marrow Transplantation (EBMT) Chronic Malignancies Working Party on myeloablative and reduced-intensity conditioning allo-transplant for myelofibrosis. This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.
